mRNA Display-based Antimicrobial Antibody Screening

With the growth of drug resistance of ESKAPEE pathogens, innovative and effective treatment methods are urgently needed. The potential of antibodies for the prevention or treatment of bacterial infections is exciting, because these biological agents do not have small molecular toxicity barriers and have narrow spectra (only for one pathogenic species), thus avoiding the destruction of the microbiome. CD BioSciences has many years of research experience in the field of antibody discovery, and is committed to providing global customers with antibacterial antibody discovery and screening services using its mRNA display-based antibody discovery platform.

Introduction to Antibacterial Antibodies

Antibiotics have become an indispensable part of medicine, and their availability, effectiveness and low cost are taken for granted. However, after decades of use and abuse of broad-spectrum antibiotics and failure to develop new antibiotics with alternative mechanisms, drug resistance has become an epidemic. In addition to the influence of antibiotics on the drug resistance rate, more and more evidence shows that broad-spectrum antibiotics interfere with our normal beneficial microbiome. These microbiome disorders or disaccharides disorders are not only related to the significant increase of Clostridium difficile related diarrhea, but also related to diabetes, obesity, immune deficiency and antibiotic resistance transmitted through horizontal gene transfer.

One method being explored is to use pathogen specific monoclonal antibodies (mAb) to prevent infection or use antibiotics to assist in the treatment of infection. Antibodies are natural proteins produced by the adaptive immune system. Using mAb with excellent functional activity to passively immunize individuals can not only neutralize bacterial virulence, but also utilize the host's immune response to pathogens.

Fig. 1 Potential mode of actions of antibacterial mAbs. (Oleksiewicz, et al., 2012)

Advantages of Antimicrobial Antibodies

The first advantage of anti-bacterial antibodies over traditional antibiotics is accuracy. They can specifically kill specific kinds of bacteria, minimize the generation of drug resistance and maintain the stability of the organism's microbiome. Another advantage of antibacterial antibodies is that both treatment and prevention are applicable. It has been found that the engineering transformation of antibacterial antibody (MEDI-4893) can play a role in prevention in advance. Currently marketed drugs such as Raxibacumab and Obiltoxaximab can be used to prevent Bacillus anthracis infection in advance. Therefore, it is of great research value to screen engineered recombinant antibodies for the treatment and prevention of viral infection by in vitro display technology.

Our Services

CD BioSciences has built a high-throughput antibody discovery platform based on mRNA display technology, which can provide customers around the world with antibody screening services targeting different bacterial targets. Our antibody discovery platform does not need complex cell transformation. Using a series of immune methods, we can achieve rapid and efficient in vitro screening, and obtain target antibody molecules and gene sequence information with high specificity and high affinity.

• Targeted bacteria provided by us include but are not limited to:

Staphylococcus aureus
Escherichia coli

Bacillus anthracis
Clostridium difficile

Pseudomonas paeruginosa

• We provide screening services for single target and multiple targets. Target can include two types:
  Bacterial surface antigen, such as capsular polysaccharide, surface protein, etc.
  Toxin secreted by bacteria, such as α toxin (Staphylococcus aureus), toxin B (Clostridium difficile), etc.

Service Features

CD BioSciences has many years of project development experience in antibody discovery. Based on the mRNA display technology platform, it can provide customers with various types of antibody screening services. If you are interested in our services, please contact us for more details.

References

1. Oleksiewicz, M. B., Nagy, G., & Nagy, E. (2012). Anti-bacterial monoclonal antibodies: back to the future? Archives of biochemistry and biophysics, 526(2), 124–131.
2. DiGiandomenico, A., & Sellman, B. R. (2015). Antibacterial monoclonal antibodies: the next generation? Current opinion in microbiology, 27, 78–85.

Related Services

• mRNA Display-based Anti-cancer Antibody Screening
• mRNA Display-based Antiviral Antibody Screening
• mRNA Display-based Bispecific Antibody Screening